Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy? - 16/08/20
, Nuno Marques, MD d, e, f, Liliana Reis, MD g, Inês Cruz, MD h, Nuno Craveiro, MD i, Hugo Antunes, MD j, Carolina Lourenço, MD k, Renata Gomes, MD l, Rui Azevedo Guerreiro, MD m, Ricardo Faria, MD n, Fernando Sá, MD o, Rui Lima, MD p, Paulo Gaspar, PhD q, r, Rui Faria, MD s, Gabriel Miltenberger-Miltenyi, PhD b, c, t, Nuno Sousa, MD, PhD b, c, Damião Cunha, MD, PhD b, cOn behalf of the group of investigators
Abstract |
Background |
Fabry disease (FD) is a treatable cause of hypertrophic cardiomyopathy (HCM). We aimed to determine the independent predictors of FD and to define a clinically useful strategy to discriminate FD among HCM.
Methods |
Multicenter study including 780 patients with the ESC definition of HCM. FD screening was performed by enzymatic assay in males and genetic testing in females. Multivariate regression analysis identified independent predictors of FD in HCM. A discriminant function analysis defined a score based on the weighted combination of these predictors.
Results |
FD was found in 37 of 780 patients with HCM (4.7%): 31 with p.F113L mutation due to a founder effect; and 6 with other variants (p.C94S; p.M96V; p.G183V; p.E203X; p.M290I; p.R356Q/p.G360R). FD prevalence in HCM adjusted for the founder effect was 0.9%. Symmetric HCM (OR 3.464, CI95% 1.151-10.430), basal inferolateral late gadolinium enhancement (LGE) (OR 10.677, CI95% 3.633-31.380), bifascicular block (OR 10.909, CI95% 2.377-50.059) and ST-segment depression (OR 4.401, CI95% 1.431-13.533) were independent predictors of FD in HCM. The score ID FABRY-HCM [−0.729 + (2.781xBifascicular block) + (0.590xST depression) + (0.831xSymmetric HCM) + (2.130xbasal inferolateral LGE)] had a negative predictive value of 95.8% for FD, with a cut-off of 1.0, meaning that, in the absence of both bifascicular block and basal inferolateral LGE, FD is a less probable cause of HCM, being more appropriate to perform HCM gene panel than targeted FD screening.
Conclusion |
FD prevalence in HCM was 0.9%. Bifascicular block and basal inferolateral LGE were the most powerful predictors of FD in HCM. In their absence, HCM gene panel is the most appropriate step in etiological study of HCM.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 226
P. 114-126 - Agosto 2020 Ritorno al numero
Articolo precedente
- Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
- Larry R. Jackson, Sunghee Kim, Rosalia Blanco, Laine Thomas, Jack Ansell, Gregg C. Fonarow, Bernard J. Gersh, Alan S. Go, Peter R. Kowey, Kenneth W. Mahaffey, Elaine M. Hylek, Eric D. Peterson, Jonathan P. Piccini, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
- Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?
- Andrew C.T. Ha, John Stewart, George Klein, Denis Roy, Stuart Connolly, Andrew Koren, Paul Dorian
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?